EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines

Mireya L Borrajo, Gustavo Lou, Shubaash Anthiya, Philipp Lapuhs, David Moreira Álvarez, Araceli Tobío, María Isabel Loza, Anxo Vidal, María José Alonso iD

Drug Delivery and Translational Research · 2024

DOI: 10.1007/s13346-024-01635-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Mireya L Borrajo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiag…. Hauptthemen laut MEDLINE: Administration, Intranasal, Nanocapsules, mRNA Vaccines, Emulsions. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade de Santiago de Compostela.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global emergency of coronavirus disease 2019 (COVID-19) has spurred extensive worldwide efforts to develop vaccines for protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our contribution to this global endeavor involved the development of a diverse library of nanocarriers, as alternatives to lipid nanoparticles (LNPs), including nanoemulsions (NEs) and nanocapsules (NCs), with the aim of protecting and delivering messenger ribonucleic acid (mRNA) for nasal vaccination purposes. A wide range of prototypes underwent rigorous screening through a series of in vitro and in vivo experiments, encompassing assessments of cellular transfection, cytotoxicity, and intramuscular administration of a model mRNA for protein translation. As a result, two promising candidates were identified for nasal administration. One of them was a NE incorporating a combination of an ionizable lipid (C12-200) and cationic lipid (DOTAP), both intended to condense mRNA, along with DOPE, which is known to facilitate endosomal escape. This NE exhibited a size of 120 nm and a highly positive surface charge (+ 50 mV). Another candidate was an NC formulation comprising the same components and endowed with a dextran sulfate shell. This formulation showed a size of 130 nm and a moderate negative surface charge (-16 mV). Upon intranasal administration of mRNA encoding for ovalbumin (mOVA) associated with optimized versions of the said NE and NCs, a robust antigen-specific CD8 + T cell response was observed. These findings underscore the potential of NEs and polymeric NCs in advancing mRNA vaccine development for combating infectious diseases. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, IntranasalNanocapsulesmRNA VaccinesEmulsionsCOVID-19 VaccinesAnimalsMiceCOVID-19NanoparticlesHumansSARS-CoV-2FemaleQuaternary Ammonium CompoundsMice, Inbred BALB CFatty Acids, MonounsaturatedRNA, MessengerDrug Carriers

Stichwörter der Autor:innen

Intranasal vaccinationNanoparticlesPolymeric nanocapsuleSARS-CoV-2mRNA vaccine

Substanzen

NanocapsulesmRNA VaccinesEmulsionsCOVID-19 Vaccines1,2-dioleoyloxy-3-(trimethylammonium)propaneQuaternary Ammonium CompoundsFatty Acids, MonounsaturatedRNA, MessengerDrug Carriers

Autor:innen und Institutionen

  • Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.
  • Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain.
  • IDIS Research Institute, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain.
  • Biofarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain.
  • Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University de Santiago de Compostela, Av. Barcelona s/n, Campus Vida, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.
  • Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.

ORCID-Profile: María José Alonso

Förderung

  • Universidade de Santiago de Compostela

Zitieren

APA

Borrajo, M. L., Lou, G., Anthiya, S., Lapuhs, P., Álvarez, D. M., Tobío, A., Loza, M. I., Vidal, A., & Alonso, M. J. (2024). Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01635-5

Vancouver

Borrajo ML, Lou G, Anthiya S, Lapuhs P, Álvarez DM, Tobío A, et al. Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01635-5

BibTeX
@article{Borrajo2024,
  author = {Borrajo, Mireya L and Lou, Gustavo and Anthiya, Shubaash and Lapuhs, Philipp and Álvarez, David Moreira and Tobío, Araceli and Loza, María Isabel and Vidal, Anxo and Alonso, María José},
  title = {Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  doi = {10.1007/s13346-024-01635-5}
}
Kostenlos starten →